Mylan Launches Hulio (adalimumab- biosimilar) in EU for Autoimmune Diseases
Shots:
- AbbVie's Humira biosimilar- Hulio received EU approval in Sep 2018- reviewing CHMP approval which included biosimilarity data regarding analytical- functional- clinical and immunogenicity of Hulio with Humira
- The launch of Hulio post EU approval is available in all 28 EU member countries including Norway- Iceland and Liechtenstein. In July- 2018 Humira had brand sales of ~$4.3B in EU
- Adalimumab IV is a TNFi indicated for treatment of autoimmune diseases. In H1’18- Mylan and Kyowa Kirin entered into a collaboration for Hulio’s commercialization in EU
Ref: Mylan| Image: Investor Business Daily
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com